KR102465341B1 - 간, 담관 및 췌장 장애의 치료 - Google Patents

간, 담관 및 췌장 장애의 치료 Download PDF

Info

Publication number
KR102465341B1
KR102465341B1 KR1020187033643A KR20187033643A KR102465341B1 KR 102465341 B1 KR102465341 B1 KR 102465341B1 KR 1020187033643 A KR1020187033643 A KR 1020187033643A KR 20187033643 A KR20187033643 A KR 20187033643A KR 102465341 B1 KR102465341 B1 KR 102465341B1
Authority
KR
South Korea
Prior art keywords
defensin
hbd
fat
liver
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187033643A
Other languages
English (en)
Korean (ko)
Other versions
KR20190003592A (ko
Inventor
페터 노르드킬드
소렌 크예룰프
Original Assignee
디펜신 테라퓨틱스 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디펜신 테라퓨틱스 에이피에스 filed Critical 디펜신 테라퓨틱스 에이피에스
Publication of KR20190003592A publication Critical patent/KR20190003592A/ko
Application granted granted Critical
Publication of KR102465341B1 publication Critical patent/KR102465341B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187033643A 2016-04-29 2017-04-28 간, 담관 및 췌장 장애의 치료 Active KR102465341B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201670276 2016-04-29
DKPA201670276 2016-04-29
DKPA201670484 2016-07-01
DKPA201670484 2016-07-01
PCT/DK2017/050132 WO2017186250A1 (en) 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders

Publications (2)

Publication Number Publication Date
KR20190003592A KR20190003592A (ko) 2019-01-09
KR102465341B1 true KR102465341B1 (ko) 2022-11-09

Family

ID=58992579

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033643A Active KR102465341B1 (ko) 2016-04-29 2017-04-28 간, 담관 및 췌장 장애의 치료

Country Status (11)

Country Link
US (1) US12076368B2 (cg-RX-API-DMAC7.html)
EP (1) EP3448409B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019514908A (cg-RX-API-DMAC7.html)
KR (1) KR102465341B1 (cg-RX-API-DMAC7.html)
CN (1) CN109414474B (cg-RX-API-DMAC7.html)
AU (1) AU2017258242B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018071972A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022497A1 (cg-RX-API-DMAC7.html)
RU (1) RU2740913C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201809086YA (cg-RX-API-DMAC7.html)
WO (1) WO2017186250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
JP7479381B2 (ja) * 2019-01-07 2024-05-08 アエスクルス バイオ エーピーエス 治療または予防に使用するためのディフェンシン断片
CN110279851A (zh) * 2019-07-05 2019-09-27 浙江大学 Defa4细胞因子在制备治疗肝功能衰竭药剂中的应用
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用
KR102735773B1 (ko) * 2022-11-10 2024-11-27 을지대학교 산학협력단 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104971343A (zh) * 2015-07-13 2015-10-14 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063A (zh) * 2015-10-19 2016-04-20 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
AU2003231947A1 (en) 2002-05-31 2003-12-19 Aaron Diamond Aids Research Center Defensins: use as antiviral agents
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US20100104529A1 (en) 2006-05-01 2010-04-29 England Robert L TNF-alpha VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-alpha
CA2655022A1 (en) 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent
WO2008115390A2 (en) 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
HUE044174T2 (hu) 2008-02-01 2019-10-28 Ascendis Pharma As Önhasítható linkert tartalmazó elõvegyület
JP2011528332A (ja) 2008-07-18 2011-11-17 ノボザイムス アデニウム バイオテック アクティーゼルスカブ 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置
CA2750727A1 (en) 2008-07-18 2010-01-21 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins
CN102317315A (zh) 2009-02-11 2012-01-11 诺维信生物制药丹麦公司 白蛋白变体和缀合物
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
US20110311601A1 (en) 2010-06-22 2011-12-22 Michael Kleine Antimicrobial medical devices
DE102010040153A1 (de) 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
JP2014520159A (ja) 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
US9217021B2 (en) * 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
BR112015004734A2 (pt) * 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
AU2017212534A1 (en) 2016-01-26 2018-07-26 Defensin Therapeutics Aps Methods for modulating intestinal microbiota
WO2017185549A1 (zh) * 2016-07-30 2017-11-02 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法2
CN114075585A (zh) * 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种β-烟酰胺单核苷酸的制备方法
CN112795606B (zh) * 2021-04-14 2021-07-27 深圳瑞德林生物技术有限公司 一种β-烟酰胺单核苷酸的酶催化合成方法
CN114107160B (zh) * 2021-12-27 2025-04-25 浙江英沃迪生物科技有限公司 一种烟酰胺核糖激酶基因工程菌及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104971343A (zh) * 2015-07-13 2015-10-14 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063A (zh) * 2015-10-19 2016-04-20 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用

Also Published As

Publication number Publication date
CN109414474B (zh) 2024-07-02
CA3022497A1 (en) 2017-11-02
RU2740913C2 (ru) 2021-01-21
EP3448409A1 (en) 2019-03-06
EP3448409B1 (en) 2025-12-03
CN109414474A (zh) 2019-03-01
RU2018141326A3 (cg-RX-API-DMAC7.html) 2020-08-06
RU2018141326A (ru) 2020-05-29
SG11201809086YA (en) 2018-11-29
AU2017258242A1 (en) 2018-11-29
US20190192626A1 (en) 2019-06-27
WO2017186250A1 (en) 2017-11-02
AU2017258242B2 (en) 2024-04-04
KR20190003592A (ko) 2019-01-09
JP2019514908A (ja) 2019-06-06
BR112018071972A2 (pt) 2019-02-26
US12076368B2 (en) 2024-09-03

Similar Documents

Publication Publication Date Title
JP6890135B2 (ja) 腸内微生物叢を調節するための方法
KR102465341B1 (ko) 간, 담관 및 췌장 장애의 치료
Canfora et al. Short-chain fatty acids in control of body weight and insulin sensitivity
RU2635966C2 (ru) Фармацевтическая композиция для предупреждения или лечения неалкогольной жировой болезни печени
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
US20050245441A1 (en) Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
JP2007531711A5 (cg-RX-API-DMAC7.html)
US20230040594A1 (en) Milk-derived polypeptide derivative, composition and method for preventing and treating obesity
KR20230023059A (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
US10800826B2 (en) Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
JP2020059735A (ja) 神経性状態および神経変性状態の治療としての長時間作用型ＧＬＰ−１ｒアゴニスト
BR112016027595B1 (pt) Produto de peptídeos, composição farmacêutica e seus usos
KR20240021212A (ko) 비만 및 비만-관련 장애의 치료
KR20200060274A (ko) 퇴행성 신경질환의 예방 또는 치료용 약학 조성물
US10005838B2 (en) Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
KR20200110342A (ko) 암을 치료하거나 예방하기 위한 조합 치료법
KR20200110343A (ko) 암을 치료하거나 예방하기 위한 조합 치료법
HK40001163B (en) Methods for modulating intestinal microbiota
JP2024018924A (ja) Ｇｌｐ－１分泌促進用組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181120

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200424

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220224

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220810

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221104

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221107

End annual number: 3

Start annual number: 1

PG1601 Publication of registration